The case for & against
Bull & Bear analysis
Bearish
Passage Bio, Inc. (NASDAQ: PASG) is a biotechnology company dedicated to developing transformative gene therapies for central nervous system (CNS) disorders, particularly those with significant unmet needs. The company has established a strong partnership with the University of Pennsylvania's gene therapy program and has progressed its pipeline to address both pediatric and adult CNS conditions, demonstrating a strategic focus on delivering innovative gene therapies in a highly competitive market.
Bull says
- ↑GM1 gangliosidosis and frontotemporal dementia trials show positive IMAGINE-1 interim results.
- ↑$189.6M cash as of Q4 2022 funds operations into mid-2025.
- ↑Mid-2023 safety and biomarker data from cohort 4 may boost trial credibility.
- ↑High institutional 13F ownership suggests strong investor confidence.
- ↑Attractive book-to-price ratio and robust liquidity underpin valuation.
- ↑Focus on unmet CNS disorders positions PASG in personalized medicine trend.
Bear says
- ↓Q4 2022 net loss of $27.1M reflects persistent unprofitability.
- ↓Negative earnings yield and poor profitability metrics indicate underperformance.
- ↓23% workforce reduction may impair clinical trial capacity.
- ↓Only ~10% pre-genotyped patient pool slows enrollment in GM1 and FTD programs.
- ↓High stock volatility underscores speculative risk and potential share price swings.
- ↓Negative growth outlook casts doubt on future revenue expansion.
Earnings Call · Q4 2021 · Mgmt. Guidance
Updated 07-02-2026neutral
Transcript signals
Bull points
- We expect our cash, cash equivalents, and marketable securities to fund our operations to year-end 2023.
- we feel very confident that we can fund our operations until the end of 2023, but of course we can continue to focus on cash management and refine how we're investing behind not only our key programs, but there are other expenses that support the company's infrastructure.
- we feel very confident that we can fund our operations until the end of 2023, but of course we can continue to focus on cash management and refine how we're investing behind not only our key programs, but there are other expenses that support the company's infrastructure.
Bear points
- Net loss was $51.2 million and $185.4 million for the quarter and year ended December 31st, 2021.
- Generally, we do expect our cash burn to be relatively consistent with prior orders and continue to be within the range, as you've seen there, about $35 to $45 million per quarter.
- Generally, we do expect our cash burn to be relatively consistent with prior orders and continue to be within the range, as you've seen there, about $35 to $45 million per quarter.
Read full transcript analysis ›